Sarepta Therapeutics (NASDAQ:SRPT) Downgraded to Hold Rating by Wall Street Zen

Wall Street Zen downgraded shares of Sarepta Therapeutics (NASDAQ:SRPT) from a buy rating to a hold rating in a research report sent to investors on Saturday.

Several other equities analysts also recently commented on the company. Wolfe Research upgraded Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 target price for the company in a research report on Thursday, July 9th. HC Wainwright reiterated a “buy” rating on shares of Sarepta Therapeutics in a research note on Tuesday, July 28th. Piper Sandler cut their price objective on Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating for the company in a report on Thursday, July 9th. Zacks Research downgraded shares of Sarepta Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 7th. Finally, Weiss Ratings lowered shares of Sarepta Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a report on Wednesday. Nine research analysts have rated the stock with a Buy rating, five have given a Hold rating and six have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $25.06.

Sarepta Therapeutics Stock Performance

NASDAQ:SRPT opened at $16.78 on Friday. Sarepta Therapeutics has a 12-month low of $14.68 and a 12-month high of $25.32. The company has a quick ratio of 2.62, a current ratio of 4.42 and a debt-to-equity ratio of 0.55. The firm has a market capitalization of $1.77 billion, a PE ratio of -5.79, a price-to-earnings-growth ratio of 0.18 and a beta of 0.23. The firm has a 50-day moving average price of $16.92 and a 200 day moving average price of $18.51.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $3.16 EPS for the quarter, topping analysts’ consensus estimates of $0.98 by $2.18. Sarepta Therapeutics had a negative net margin of 13.48% and a negative return on equity of 1.60%. The firm had revenue of $730.80 million during the quarter, compared to analysts’ expectations of $474.15 million. During the same quarter last year, the company earned ($3.42) earnings per share. The company’s revenue for the quarter was down 1.9% compared to the same quarter last year. Research analysts anticipate that Sarepta Therapeutics will post 3.89 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sarepta Therapeutics

Several institutional investors have recently bought and sold shares of the business. Kestra Advisory Services LLC acquired a new position in Sarepta Therapeutics in the fourth quarter worth $25,000. iSAM Funds UK Ltd bought a new position in shares of Sarepta Therapeutics in the third quarter valued at about $25,000. Ancora Advisors LLC raised its holdings in shares of Sarepta Therapeutics by 200.0% in the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 1,000 shares during the last quarter. Meeder Asset Management Inc. acquired a new position in Sarepta Therapeutics during the 2nd quarter worth about $27,000. Finally, Allworth Financial LP grew its holdings in Sarepta Therapeutics by 2,098.8% during the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 1,721 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics News Summary

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Options activity turned notably bullish: traders purchased 4,625 call options on Friday, about 47% above the typical daily volume of 3,153 contracts. This suggests increased speculative interest in an upside move, although options activity does not guarantee a sustained rally.
• Positive Sentiment: Sarepta exceeded Wall Street expectations in the second quarter of 2026, reporting earnings of $0.64 per share versus the $0.58 consensus estimate and delivering a revenue beat of approximately 12.85%. The company also reported $13 million in GAAP operating income, highlighting improved profitability. Sarepta Q2 earnings and revenue results
• Positive Sentiment: Management emphasized progress in its siRNA pipeline and a strategic shift under its recently appointed chief executive officer. Pipeline advances could help diversify Sarepta beyond its current commercial products and strengthen the longer-term investment case. Sarepta Q2 earnings call highlights
• Neutral Sentiment: The company’s financial performance improved, but reported earnings were below the $2.02 per-share result from the same quarter last year. Investors may therefore focus on whether the profitability gains are sustainable.
• Negative Sentiment: Elevidys sales were weaker than expected, and Sarepta narrowed its 2026 product-revenue outlook while tightening expense guidance. The lower outlook could offset the positive impact of the quarterly earnings and revenue beats. Sarepta Q2 earnings and 2026 outlook
• Negative Sentiment: RBC highlighted competitive pressures despite Sarepta’s pipeline updates. That raises concerns about Elevidys’ future sales trajectory and the company’s ability to maintain growth in a more competitive rare-disease market. RBC analysis of Sarepta competitive pressures

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.